ArticleMolecular biology reports2026
Ferroptosis, DNA damage repair, and transporter proteins: associated with platinum sensitivity and prognosis in epithelial ovarian cancer.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveThis study aimed to links between ATP7B, CTR1, GPX4, 53BP1, p-H2AX and p-ATM expression, platinum sensitivity and prognosis in patients with epithelial ovarian cancer (EOC).
methodsThis study integrated clinical research, in vitro experiments, and database analysis, incorporating immunohistochemistry (IHC) of EOC tissues and survival analyses based on Kaplan-Meier and Cox regression models, expression differences of proteins in platinum-sensitive and platinum-resistant ovarian cancer cell lines, as well as cross-validation utilizing public transcriptome databases.
resultsPatients with EOC with high expression levels of CTR1, 53BP1, and p-H2AX, and low expression levels of ATP7B, GPX4, and p-ATM exhibited increased sensitivity to platinum-based chemotherapeutic agents, whereas those with high protein expression levels of CTR1, 53BP1, and p-H2AX, and low expression levels of GPX4, exhibited longer overall survival. However, the protein levels of p-ATM and ATP7B were not significantly correlated with the prognosis of EOC. Analysis of the KM-pPlotter database indicated revealed that high mRNA levels of CTR1 and H2AX, coupled with low mRNA levels of GPX4 and ATM, were associated with a better prognosis; however, the mRNA levels of 53BP1 and ATP7B were not significantly correlated with prognosis of EOC.
conclusionsHigh expression levels of CTR1, 53BP1, and p-H2AX, along with low expression levels of ATP7B, GPX4, and p-ATM, may be associated with platinum sensitivity in patients with EOC. Furthermore, the protein expression levels of 53BP1, H2AX, CTR1, and GPX4 may be correlated with survival rate in patients with EOC and prognosis of EOC.
Indexed as
Identifiers
42593694What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.